Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774478 | 0.84 | ALOX15 (0.36) | ALDH1A1 | |
| SCHEMBL22499925 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL909896 | 0.76 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL29165215 | 0.76 | — | — | |
| SCHEMBL3295125 | 0.75 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL1066713 | 0.74 | MGAM (0.56) | ALDH1A1TSHR | |
| SCHEMBL8642435 | 0.73 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| SCHEMBL2144683 | 0.73 | MGAM (0.39) | ALDH1A1TSHR | |
| SCHEMBL371452 | 0.73 | ALDH1A1 (0.55) | ALDH1A1TSHR | |
| SCHEMBL1067977 | 0.73 | CES1 (0.37) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102344-A1 | METERED DOSE INHALERS AND SUSPENSION COMPOSITIONS | KINDEVA DRUG DELIVERY LP (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4110442-B1 | INHALER | KINDEVA DRUG DELIVERY LP (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-3880169-B1 | UMECLIDINIUM AND VILANTEROL FORMULATION AND INHALER | KINDEVA DRUG DELIVERY LP (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12220525-B2 | Tiotropium formulation and inhaler | KINDEVA DRUG DELIVER L.P. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20250009653-A1 | PROPELLANTS FOR ANTICHOLINERGIC AGENTS IN PRESSURIZED METERED DOSE INHALERS | JPMORGAN CHASE BANK, N.A. | 2025-01-09 | — | — | US | disclosed |
| US-20240382419-A1 | METERED DOSE INHALERS AND SOLUTION COMPOSITIONS | JPMORGAN CHASE BANK, N.A. | 2024-11-21 | — | — | US | disclosed |
| EP-4398879-A1 | METERED DOSE INHALERS AND SOLUTION COMPOSITIONS | Kindeva Drug Delivery L.P. (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-4398880-A1 | METERED DOSE INHALERS AND SUSPENSION COMPOSITIONS | Kindeva Drug Delivery L.P. (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-4398881-A1 | PROPELLANTS FOR ANTICHOLINERGIC AGENTS IN PRESSURIZED METERED DOSE INHALERS | Kindeva Drug Delivery L.P. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240226004-A1 | FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION | JPMORGAN CHASE BANK, N.A. | 2024-07-11 | — | — | US | disclosed |
| US-20120097159-A1 | MEDICINAL INHALATION DEVICES AND COMPONENTS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2012-04-26 | — | — | US | disclosed |
| EP-2427278-A1 | MEDICINAL INHALATION DEVICES AND COMPONENTS THEREOF | 3M Innovative Properties Company (US) | 2012-03-14 | — | — | EP | disclosed |
| US-8104469-B2 | Medicinal inhalation devices and components thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| WO-2010129758-A1 | MEDICINAL INHALATION DEVICES AND COMPONENTS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100263667-A1 | MEDICINAL INHALATION DEVICES AND COMPONENTS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100258119-A1 | MEDICINAL INHALATION DEVICES AND COMPONENTS THEREOF | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2010-10-14 | — | — | US | disclosed |
| EP-2205301-A2 | MEDICINAL INHALATION DEVICES AND COMPONENTS THEREOF | 3M Innovative Properties Company (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2205300-A2 | MEDICINAL INHALATION DEVICES AND COMPONENTS THEREOF | 3M Innovative Properties Company (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009061902-A2 | MEDICINAL INHALATION DEVICES AND COMPONENTS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009061907-A2 | MEDICINAL INHALATION DEVICES AND COMPONENTS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102344-A1 | METERED DOSE INHALERS AND SUSPENSION COMPOSITIONS | ADRA1D, CHRND, ADRB2 | ALDH1A1 1878/4885TSHR 646/4885 |
| US-20240226004-A1 | FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION | MCOLN3, SYMPK, ADRB2 | ALDH1A1 3049/4885TSHR 2005/4885 |
| US-12220525-B2 | Tiotropium formulation and inhaler | TMCO1, CACNA1G, CACNA1H | ALDH1A1 1681/4885TSHR 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.